. 2016 Jan 28;27(7):2164–2176. doi: 10.1681/ASN.2015040369

Table 2.

Safety and compliance parameters in the study arms

Parameter and Study Moment	KD (n=104)	LPD (n=103)	P Value^b
SGA A, %
Baseline	86	90	0.29
End of study	83	82	0.83
BMI (kg/m²)
Baseline	23.6 (23.1 to 24.2)	23.2 (22.7 to 23.7)	0.20
End of study	23.3 (22.9 to 23.7)	23.1 (22.6 to 23.5)	0.45
TSF (cm)
Baseline	20.0 (19.6 to 20.4)	19.9 (19.8 to 20.3)	0.82
End of study	19.8 (19.3 to 20.1)	19.7 (19.5 to 20.1)	0.94
MAMC (cm)
Baseline	23.4 (23.1 to 23.6)	23.2 (22.9 to 23.4)	0.46
End of study	23.1 (22.8 to 23.5)	22.8 (22.7 to 23.2)	0.26
CRP (mg/L)^a
Baseline	4.6 (4.1 to 5.1)	4.4 (3.9 to 4.8)	0.45
End of study	4.8 (4.3 to 5.4)	6.4 (5.7 to 7.0)	<0.01
Serum albumin (g/dl)^b
Baseline	4.1 (4.1 to 4.2)	4.1 (4.1 to 4.2)	0.51
End of study	4.1 (4.0 to 4.1)	4.1 (4.1 to 4.2)	0.65
Serum total cholesterol (mg/dl)
Baseline	225.5 (218.0 to 232.0)	217.0 (214.0 to 222.0)	0.06
End of study	198.4 (190.8 to 206.0)	197.7 (192.0 to 203.4)	0.87
Serum potassium (mEq/L)^c
Baseline	4.7 (4.4 to 5.0)	4.2 (4.1 to 4.4)	0.001
End of study	4.9 (4.7 to 5.0)	4.6 (4.5 to 4.7)	0.12
Protein intake (g/kg per day)
Baseline	0.61 (0.58 to 0.62)	0.60 (0.58 to 0.61)	0.84
End of study	0.29 (0.29 to 031)	0.58 (0.57 to 0.59)	<0.01
Energy intake (kcal/kg per day)
Baseline	31.0 (30.2 to 31.6)	30.5 (30.0 to 31.0)	0.26
End of study	30.5 (29.5 to 31.5)	30.2 (29.8 to 30.8)	0.99

Values at randomization were compared with those at the end of the study (i.e., reach of the EPP or end of the follow-up period). Data are shown as median and 95% CI. BMI, body mass index; TSF, tricipital skinfolds; MAMC, midarm muscular circumference.